Back to Course

2025 PACUPrep BCCCP Preparatory Course

0% Complete
0/0 Steps
  1. Pulmonary

    ARDS
    4 Topics
    |
    1 Quiz
  2. Asthma Exacerbation
    4 Topics
    |
    1 Quiz
  3. COPD Exacerbation
    4 Topics
    |
    1 Quiz
  4. Cystic Fibrosis
    6 Topics
    |
    1 Quiz
  5. Drug-Induced Pulmonary Diseases
    3 Topics
    |
    1 Quiz
  6. Mechanical Ventilation Pharmacotherapy
    5 Topics
    |
    1 Quiz
  7. Pleural Disorders
    5 Topics
    |
    1 Quiz
  8. Pulmonary Hypertension (Acute and Chronic severe pulmonary hypertension)
    5 Topics
    |
    1 Quiz
  9. Cardiology
    Acute Coronary Syndromes
    6 Topics
    |
    1 Quiz
  10. Atrial Fibrillation and Flutter
    6 Topics
    |
    1 Quiz
  11. Cardiogenic Shock
    4 Topics
    |
    1 Quiz
  12. Heart Failure
    7 Topics
    |
    1 Quiz
  13. Hypertensive Crises
    5 Topics
    |
    1 Quiz
  14. Ventricular Arrhythmias and Sudden Cardiac Death Prevention
    5 Topics
    |
    1 Quiz
  15. NEPHROLOGY
    Acute Kidney Injury (AKI)
    5 Topics
    |
    1 Quiz
  16. Contrast‐Induced Nephropathy
    5 Topics
    |
    1 Quiz
  17. Drug‐Induced Kidney Diseases
    5 Topics
    |
    1 Quiz
  18. Rhabdomyolysis
    5 Topics
    |
    1 Quiz
  19. Syndrome of Inappropriate Antidiuretic Hormone (SIADH)
    5 Topics
    |
    1 Quiz
  20. Renal Replacement Therapies (RRT)
    5 Topics
    |
    1 Quiz
  21. Neurology
    Status Epilepticus
    5 Topics
    |
    1 Quiz
  22. Acute Ischemic Stroke
    5 Topics
    |
    1 Quiz
  23. Subarachnoid Hemorrhage
    5 Topics
    |
    1 Quiz
  24. Spontaneous Intracerebral Hemorrhage
    5 Topics
    |
    1 Quiz
  25. Neuromonitoring Techniques
    5 Topics
    |
    1 Quiz
  26. Gastroenterology
    Acute Upper Gastrointestinal Bleeding
    5 Topics
    |
    1 Quiz
  27. Acute Lower Gastrointestinal Bleeding
    5 Topics
    |
    1 Quiz
  28. Acute Pancreatitis
    5 Topics
    |
    1 Quiz
  29. Enterocutaneous and Enteroatmospheric Fistulas
    5 Topics
    |
    1 Quiz
  30. Ileus and Acute Intestinal Pseudo-obstruction
    5 Topics
    |
    1 Quiz
  31. Abdominal Compartment Syndrome
    5 Topics
    |
    1 Quiz
  32. Hepatology
    Acute Liver Failure
    5 Topics
    |
    1 Quiz
  33. Portal Hypertension & Variceal Hemorrhage
    5 Topics
    |
    1 Quiz
  34. Hepatic Encephalopathy
    5 Topics
    |
    1 Quiz
  35. Ascites & Spontaneous Bacterial Peritonitis
    5 Topics
    |
    1 Quiz
  36. Hepatorenal Syndrome
    5 Topics
    |
    1 Quiz
  37. Drug-Induced Liver Injury
    5 Topics
    |
    1 Quiz
  38. Dermatology
    Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis
    5 Topics
    |
    1 Quiz
  39. Erythema multiforme
    5 Topics
    |
    1 Quiz
  40. Drug Reaction (or Rash) with Eosinophilia and Systemic Symptoms (DRESS)
    5 Topics
    |
    1 Quiz
  41. Immunology
    Transplant Immunology & Acute Rejection
    5 Topics
    |
    1 Quiz
  42. Solid Organ & Hematopoietic Transplant Pharmacotherapy
    5 Topics
    |
    1 Quiz
  43. Graft-Versus-Host Disease (GVHD)
    5 Topics
    |
    1 Quiz
  44. Hypersensitivity Reactions & Desensitization
    5 Topics
    |
    1 Quiz
  45. Biologic Immunotherapies & Cytokine Release Syndrome
    5 Topics
    |
    1 Quiz
  46. Endocrinology
    Relative Adrenal Insufficiency and Stress-Dose Steroid Therapy
    5 Topics
    |
    1 Quiz
  47. Hyperglycemic Crisis (DKA & HHS)
    5 Topics
    |
    1 Quiz
  48. Glycemic Control in the ICU
    5 Topics
    |
    1 Quiz
  49. Thyroid Emergencies: Thyroid Storm & Myxedema Coma
    5 Topics
    |
    1 Quiz
  50. Hematology
    Acute Venous Thromboembolism
    5 Topics
    |
    1 Quiz
  51. Drug-Induced Thrombocytopenia
    5 Topics
    |
    1 Quiz
  52. Anemia of Critical Illness
    5 Topics
    |
    1 Quiz
  53. Drug-Induced Hematologic Disorders
    5 Topics
    |
    1 Quiz
  54. Sickle Cell Crisis in the ICU
    5 Topics
    |
    1 Quiz
  55. Methemoglobinemia & Dyshemoglobinemias
    5 Topics
    |
    1 Quiz
  56. Toxicology
    Toxidrome Recognition and Initial Management
    5 Topics
    |
    1 Quiz
  57. Management of Acute Overdoses – Non-Cardiovascular Agents
    5 Topics
    |
    1 Quiz
  58. Management of Acute Overdoses – Cardiovascular Agents
    5 Topics
    |
    1 Quiz
  59. Toxic Alcohols and Small-Molecule Poisons
    5 Topics
    |
    1 Quiz
  60. Antidotes and Gastrointestinal Decontamination
    5 Topics
    |
    1 Quiz
  61. Extracorporeal Removal Techniques
    5 Topics
    |
    1 Quiz
  62. Withdrawal Syndromes in the ICU
    5 Topics
    |
    1 Quiz
  63. Infectious Diseases
    Sepsis and Septic Shock
    5 Topics
    |
    1 Quiz
  64. Pneumonia (CAP, HAP, VAP)
    5 Topics
    |
    1 Quiz
  65. Endocarditis
    5 Topics
    |
    1 Quiz
  66. CNS Infections
    5 Topics
    |
    1 Quiz
  67. Complicated Intra-abdominal Infections
    5 Topics
    |
    1 Quiz
  68. Antibiotic Stewardship & PK/PD
    5 Topics
    |
    1 Quiz
  69. Clostridioides difficile Infection
    5 Topics
    |
    1 Quiz
  70. Febrile Neutropenia & Immunocompromised Hosts
    5 Topics
    |
    1 Quiz
  71. Skin & Soft-Tissue Infections / Acute Osteomyelitis
    5 Topics
    |
    1 Quiz
  72. Urinary Tract and Catheter-related Infections
    5 Topics
    |
    1 Quiz
  73. Pandemic & Emerging Viral Infections
    5 Topics
    |
    1 Quiz
  74. Supportive Care (Pain, Agitation, Delirium, Immobility, Sleep)
    Pain Assessment and Analgesic Management
    5 Topics
    |
    1 Quiz
  75. Sedation and Agitation Management
    5 Topics
    |
    1 Quiz
  76. Delirium Prevention and Treatment
    5 Topics
    |
    1 Quiz
  77. Sleep Disturbance Management
    5 Topics
    |
    1 Quiz
  78. Immobility and Early Mobilization
    5 Topics
    |
    1 Quiz
  79. Oncologic Emergencies
    5 Topics
    |
    1 Quiz
  80. End-of-Life Care & Palliative Care
    Goals of Care & Advance Care Planning
    5 Topics
    |
    1 Quiz
  81. Pain Management & Opioid Therapy
    5 Topics
    |
    1 Quiz
  82. Dyspnea & Respiratory Symptom Management
    5 Topics
    |
    1 Quiz
  83. Sedation & Palliative Sedation
    5 Topics
    |
    1 Quiz
  84. Delirium Agitation & Anxiety
    5 Topics
    |
    1 Quiz
  85. Nausea, Vomiting & Gastrointestinal Symptoms
    5 Topics
    |
    1 Quiz
  86. Management of Secretions (Death Rattle)
    5 Topics
    |
    1 Quiz
  87. Fluids, Electrolytes, and Nutrition Management
    Intravenous Fluid Therapy and Resuscitation
    5 Topics
    |
    1 Quiz
  88. Acid–Base Disorders
    5 Topics
    |
    1 Quiz
  89. Sodium Homeostasis and Dysnatremias
    5 Topics
    |
    1 Quiz
  90. Potassium Disorders
    5 Topics
    |
    1 Quiz
  91. Calcium and Magnesium Abnormalities
    5 Topics
    |
    1 Quiz
  92. Phosphate and Trace Electrolyte Management
    5 Topics
    |
    1 Quiz
  93. Enteral Nutrition Support
    5 Topics
    |
    1 Quiz
  94. Parenteral Nutrition Support
    5 Topics
    |
    1 Quiz
  95. Refeeding Syndrome and Specialized Nutrition
    5 Topics
    |
    1 Quiz
  96. Trauma and Burns
    Initial Resuscitation and Fluid Management in Trauma
    5 Topics
    |
    1 Quiz
  97. Hemorrhagic Shock, Massive Transfusion, and Trauma‐Induced Coagulopathy
    5 Topics
    |
    1 Quiz
  98. Burns Pharmacotherapy
    5 Topics
    |
    1 Quiz
  99. Burn Wound Care
    5 Topics
    |
    1 Quiz
  100. Open Fracture Antibiotics
    5 Topics
    |
    1 Quiz

Participants 432

  • Allison Clemens
  • April
  • ababaabhay
  • achoi2392
  • adhoward1
Show more
Lesson 83, Topic 4
In Progress

Supportive Care and Monitoring during Deep Sedation

Lesson Progress
0% Complete
Supportive Care and Monitoring during Deep Sedation

Supportive Care and Monitoring during Deep Sedation

Objective Icon A checkmark inside a circle, symbolizing achieved goals.

Objective

Recommend supportive care and monitoring measures to manage complications associated with deep sedation.

1. Mechanical Ventilation

Deep sedation often accompanies mechanical ventilation to ensure patient-ventilator synchrony and facilitate lung-protective strategies in critically ill patients.

Indications for Deep Sedation

  • Severe Acute Respiratory Distress Syndrome (ARDS) with PaO₂/FiO₂ < 150 mmHg despite optimized PEEP/FiO₂
  • Persistent tachypnea (Respiratory Rate >35/min) with significant accessory muscle use
  • Severe metabolic acidosis requiring controlled ventilation
  • Elevated intracranial pressure

Sedation and Synchrony Strategies

  • Sedation Targets: Initiate at a Richmond Agitation-Sedation Scale (RASS) score of –4 to –5 for severe ARDS or intracranial hypertension. Titrate to a lighter target of RASS –2 to 0 once the primary insult stabilizes.
  • Synchrony Strategies: Utilize adaptive support ventilation or proportional modes to improve patient comfort. Monitor for lung protection by maintaining tidal volumes of 4–8 mL/kg of ideal body weight and plateau pressures below 30 cm H₂O.

Weaning Protocol

A structured weaning protocol is essential. Once the patient is stable with a RASS target of –2 to 0, proceed with daily Spontaneous Awakening Trials (SATs) to assess neurologic function, followed by a Spontaneous Breathing Trial (SBT) to evaluate readiness for extubation.

Pearl IconA shield with an exclamation mark. Clinical Pearl: Coordinated Weaning +

Early, coordinated sedation breaks paired with spontaneous breathing trials have been shown to shorten the duration of mechanical ventilation and ICU length of stay without increasing the risk of adverse events like self-extubation.

2. Hemodynamic Support Strategies

Many sedative agents can cause vasodilation and negative inotropy, leading to hypotension. A strategy of balanced fluid resuscitation and tailored vasopressor use is critical to maintain end-organ perfusion.

Fluid Resuscitation

Balanced crystalloids are the first-line fluid choice. Fluid responsiveness should be assessed dynamically using methods like a passive leg raise (PLR) or stroke volume variation (SVV) from an arterial line to avoid fluid overload.

Vasopressor Therapy

  • First-line: Norepinephrine, initiated at 0.01–0.1 μg/kg/min and titrated to maintain a mean arterial pressure (MAP) of ≥65 mmHg.
  • Second-line: Add vasopressin at a fixed dose of 0.03 units/min for refractory hypotension or if norepinephrine requirements exceed 0.25 μg/kg/min to reduce catecholamine exposure.

Hemodynamic Monitoring

Continuous monitoring is essential. An arterial line provides real-time MAP and allows for assessment of pulse pressure variation. Serial lactate measurements should be trended, with a goal of >10% clearance over 2 hours indicating successful resuscitation.

Pearl IconA shield with an exclamation mark. Clinical Pearl: Early Arterial Line Placement +

Place an arterial catheter early in any patient requiring deep sedation. Non-invasive blood pressure cuffs can be inaccurate in low-flow states, potentially masking significant hypotension and delaying necessary interventions.

3. Prevention of ICU-Related Complications

Immobility from deep sedation increases the risk of iatrogenic complications. Prophylactic measures should be implemented to reduce venous thromboembolism (VTE), stress ulcers, and device-associated infections.

A. Venous Thromboembolism (VTE) Prophylaxis

  • Pharmacologic: Unless a high bleeding risk exists, use enoxaparin 40 mg subcutaneously once daily or unfractionated heparin 5,000 units subcutaneously every 8–12 hours. Consider anti-Xa level monitoring in patients with obesity or renal dysfunction.
  • Mechanical: Use intermittent pneumatic compression devices when pharmacologic anticoagulation is contraindicated. Encourage active and passive range-of-motion exercises as sedation lightens.

B. Stress-Related Mucosal Bleeding Prophylaxis

Prophylaxis is indicated for patients with coagulopathy, those on mechanical ventilation for more than 48 hours, or those requiring vasopressor support.

Common Agents for Stress Ulcer Prophylaxis
Agent Standard Dose Route Clinical Notes
Pantoprazole (PPI) 40 mg once daily IV or Enteral Preferred agent due to efficacy. May be associated with a small increased risk of pneumonia.
Ranitidine (H₂RA) 50 mg every 8 hours IV Alternative if PPI is contraindicated. Tachyphylaxis can occur after several days.

C. Catheter-Associated Infection Prevention

  • Central Line Bundle: Adhere strictly to hand hygiene, maximal sterile barrier precautions during insertion, chlorhexidine skin preparation, and daily review of line necessity.
  • Urinary Catheter Protocol: Check for necessity daily. Use securement devices to prevent movement and maintain a closed drainage system at all times.
Pearl IconA shield with an exclamation mark. Clinical Pearl: Bundle Compliance Audits +

Regular (e.g., monthly) audits of bundle compliance with transparent feedback to clinical staff have been shown to reduce central line–associated bloodstream infection (CLABSI) rates by over 50%.

4. Management of Iatrogenic Complications

Vigilant detection and prompt management are required to address common complications induced by sedation, including hypotension, respiratory depression, and delirium.

A. Sedation-Induced Hypotension

  1. Reduce the sedative infusion rate by 25% increments.
  2. Reassess volume status and perfusion markers.
  3. If MAP remains <65 mmHg after a fluid challenge, initiate or increase vasopressor support.

B. Respiratory Depression

  • Monitoring: Use continuous capnography (EtCO₂) and pulse oximetry for all deeply sedated patients, especially those receiving opioid infusions.
  • Reversal: For opioid-induced respiratory depression, administer naloxone 0.04 mg IV and titrate every 2 minutes as needed to restore adequate ventilation while attempting to preserve analgesia.

C. Delirium Management

A stepwise approach is recommended, prioritizing non-pharmacologic interventions.

Delirium Management Flowchart A flowchart showing the management pathway for ICU delirium, starting with assessment, prioritizing non-pharmacologic strategies, and using pharmacologic agents only for severe agitation. Assess for Delirium (CAM-ICU) 1. Implement Non-Pharmacologic Bundle Severe Agitation Persists? No Continue & Monitor Yes 2. Consider Haloperidol
Figure 1: Stepwise Approach to Delirium Management. Non-pharmacologic strategies are the foundation of care. Pharmacologic agents are reserved for cases of severe agitation that pose a safety risk.
Controversy IconA chat bubble with a question mark. Clinical Pitfall: Pharmacologic Delirium Treatment +

Routine pharmacologic treatment of hypoactive delirium is not recommended and may prolong ICU stay. Antipsychotics like haloperidol can prolong the QTc interval and should be used at the lowest effective dose for the shortest duration possible, primarily for hyperactive delirium causing severe agitation.

5. Multidisciplinary Goals-of-Care Conversations

The intensity and duration of deep sedation must be aligned with the patient’s values and overall prognosis. This requires regular, documented discussions involving all relevant stakeholders.

  • Stakeholders: Key participants include the primary critical care team (physicians, nurses, pharmacists, respiratory therapists), palliative care specialists, ethics consultants, and most importantly, the patient or their designated surrogate decision-maker.
  • Documentation: Conversations should be clearly documented, outlining advance directives, agreed-upon sedation ceilings (e.g., “do not exceed RASS –4”), and the duration of therapeutic trials of deep sedation.
  • Re-evaluation Triggers: Establish clear triggers for re-evaluating the goals of care, such as the development of a new organ failure, failure to improve after a predefined sedation trial, or a change in the patient’s code status.
Pearl IconA shield with an exclamation mark. Clinical Pearl: Embedding Goals in Daily Rounds +

Explicitly stating the daily sedation goal (e.g., “Today’s RASS target is -1 to 0”) during multidisciplinary rounds ensures consistent team alignment and helps prevent “sedation creep,” where deep sedation is continued unnecessarily out of habit.

6. Standardized Monitoring Protocols

Structured and consistent monitoring ensures the safety and efficacy of sedation and all associated supportive care measures, allowing for timely adjustments.

  • Sedation Depth: Assess RASS (or RASS-PAL for palliative patients) every 2–4 hours and after any dose change. The goal should be clearly defined, with a default target of RASS –2 to 0 once deep sedation is no longer clinically indicated.
  • Vital Signs: All patients on continuous sedative infusions require continuous monitoring of heart rate, blood pressure (ideally via arterial line), pulse oximetry (SpO₂), and end-tidal CO₂ (EtCO₂). Regularly verify the quality of invasive monitoring waveforms.
  • Laboratory Monitoring: Trend daily labs, including a complete blood count (CBC) and basic metabolic panel. An arterial blood gas (ABG) should be checked as needed for ventilator adjustments, and lactate levels should be trended to monitor perfusion.
Pearl IconA shield with an exclamation mark. Clinical Pearl: The Value of Capnography +

Early detection of a rising EtCO₂ in a mechanically ventilated patient can be the first sign of worsening respiratory mechanics, oversedation leading to reduced respiratory drive, or ventilator dyssynchrony. It allows for prompt adjustments before significant hypercarbia or acidemia develops.

7. Documentation and Quality Metrics

Utilizing integrated electronic health record (EHR) tools and tracking key performance indicators (KPIs) are essential for monitoring sedation practices, evaluating patient outcomes, and driving continuous quality improvement.

  • Electronic Flow Sheets: Document sedation scores, ventilator settings, vasopressor doses, and other key parameters in real time using integrated EHR flow sheets. This facilitates trend analysis and communication between shifts.
  • Key Performance Indicators (KPIs): Track unit-level metrics such as ventilator-free days, incidence of VTE, rates of stress ulcer bleeding, catheter-related infection rates (CLABSI/CAUTI), and the prevalence of delirium.
  • Continuous Improvement: Conduct monthly audits of protocol adherence (e.g., SAT/SBT, VTE prophylaxis). Use these data to provide targeted staff education and refine local guidelines.
Pearl IconA shield with an exclamation mark. Clinical Pearl: Transparent KPI Reporting +

Transparently reporting unit-level KPIs on a public dashboard or in staff meetings fosters a culture of accountability and has been shown to improve adherence to sedation, delirium, and prophylaxis protocols, ultimately improving patient outcomes.

References

  1. Barr J, Fraser GL, Puntillo K, et al. Clinical practice guidelines for the management of pain, agitation, and delirium in adult patients in the intensive care unit. Crit Care Med. 2013;41(1):263–306.
  2. Hanidziar D, Bittner EA. Monitoring sedation in mechanically ventilated patients: a narrative review. Crit Care. 2022;26(1):180.
  3. Helms J, Severac F, Merdji H, et al. Thromboprophylaxis in critical care. Ann Intensive Care. 2022;12(1):107.
  4. Khan A, Patel R, Kumar A, et al. Stress ulcer prophylaxis within the ICU. US Pharm. 2023;48(12):HS-5–HS-10.
  5. Krishnamoorthy V, Lewis K, Patanwala AE, et al. The SCCM and ASHP guideline for the prevention and management of stress-related mucosal bleeding in critically ill adults. Crit Care Med. 2024;52(7):e1234–e1247.
  6. Gitti N, Biondi-Zoccai G, De Luca L, et al. Optimal sedation strategies in the ICU. Front Med (Lausanne). 2022;9:901343.
  7. VUMC SICU VTE Prophylaxis Guideline. Vanderbilt University Medical Center; 2023.
  8. Seo Y, Lee YJ, Park S, et al. Korean Society of Critical Care Medicine (KSCCM) clinical practice guidelines for pain, agitation, and delirium in the intensive care unit. Acute Crit Care. 2022;37(1):1–27.
  9. Kim YK, Lee H, Lee YJ, et al. Korean Society of Critical Care Medicine (KSCCM) clinical practice guidelines on intensive care unit sedation and sleep management. Acute Crit Care. 2022;37(1):1–38.